FNTB inhibitors bind FNTA:FNTB

Stable Identifier
R-HSA-9647987
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Because prenylation is important for RAS membrane localization and function, inhibition of this step of RAS processing was viewed as a promising early therapeutic target for RAS-driven cancers (reviewed in Gysin et al, 2011). Farnesylttransferase inhibitors such as lonifarnib and tipifarnib are small molecule CaaX competitive inhibitors that inhibit cell growth of a range of cancer cell lines and tumor xenografts (Njoroge et al, 1998; End et al, 2001; Liu et al, 1998; Ashar et al, 2001). Unfortunately, the clinical use of these drugs is hampered by the fact that both KRAS and NRAS can be geranylgeranylated when FTase is inhibited, restoring membrane localization and function (Fiordalisi et al, 2003). FTase inhibitors may have clinical use in the treatment of HRAS driven cancers, such as bladder and thyroid cancers (reviewed in Gysin et al, 2011; Lu et al, 2016).

Literature References
PubMed ID Title Journal Year
9822558 (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent

Njoroge, FG, Taveras, AG, Kelly, J, Remiszewski, S, Mallams, AK, Wolin, R, Afonso, A, Cooper, AB, Rane, DF, Liu, YT, Wong, J, Vibulbhan, B, Pinto, P, Deskus, J, Alvarez, CS, del Rosario, J, Connolly, M, Wang, J, Desai, J, Rossman, RR, Bishop, WR, Patton, R, Wang, L, Kirschmeier, P, Ganguly, AK

J. Med. Chem. 1998
11196150 Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro

End, DW, Smets, G, Todd, AV, Applegate, TL, Fuery, CJ, Angibaud, P, Venet, M, Sanz, G, Poignet, H, Skrzat, S, Devine, A, Wouters, W, Bowden, C

Cancer Res. 2001
21779505 Therapeutic strategies for targeting ras proteins

Gysin, S, Salt, M, Young, A, McCormick, F

Genes Cancer 2011
9810004 Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice

Liu, M, Bryant, MS, Chen, J, Lee, S, Yaremko, B, Lipari, P, Malkowski, M, Ferrari, E, Nielsen, L, Prioli, N, Dell, J, Sinha, D, Syed, J, Korfmacher, WA, Nomeir, AA, Lin, CC, Wang, L, Taveras, AG, Doll, RJ, Njoroge, FG, Mallams, AK, Remiszewski, S, Catino, JJ, Girijavallabhan, VM, Bishop, WR

Cancer Res. 1998
11120601 The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines

Ashar, HR, James, L, Gray, K, Carr, D, McGuirk, M, Maxwell, E, Black, S, Armstrong, L, Doll, RJ, Taveras, AG, Bishop, WR, Kirschmeier, P

Exp. Cell Res. 2001
27396271 Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view

Lu, S, Jang, H, Gu, S, Zhang, J, Nussinov, R

Chem Soc Rev 2016
Participants
Participant Of
hasEvent
Orthologous Events
Authored
Reviewed
Created
Cite Us!